You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProparacaine
Accession NumberDB00807  (APRD00522)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionProparacaine is a topical anesthetic drug of the amino ester group. It is available as its hydrochloride salt in ophthalmic solutions at a concentration of 0.5%. [Wikipedia]
Structure
Thumb
Synonyms
Proparacaine
Proximetacaina
Proxymetacaine
Proxymetacainum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alcainesolution/ drops5 mg/mLophthalmicAlcon Laboratories, Inc.1973-10-19Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicH.J. Harkins Company, Inc.1995-09-29Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicHenry Schein Inc.2015-05-13Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicAkorn, Inc.2000-03-16Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicA S Medication Solutions Llc2000-03-16Not applicableUs
Proparacaine Hydrochloridesolution5 mg/mLophthalmicRebel Distributors Corp1995-09-29Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicSandoz Inc.2000-06-05Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicMwi2015-03-27Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicBausch & Lomb Incorporated1995-09-29Not applicableUs
Proparacaine Hydrochloridesolution/ drops5 mg/mLophthalmicPreferred Pharmaceuticals, Inc.2014-04-28Not applicableUs
Proparacaine Hydrochloridesolution5 mg/mLophthalmicSTAT Rx USA LLC2000-06-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ak-TaineNot Available
DiocaineNot Available
Ocu-CaineNot Available
OphthaineNot Available
OphtheticNot Available
Spectro-CaineNot Available
Brand mixtures
NameLabellerIngredients
FlucaineO Cu Soft, Inc.
Fluorescein Sodium and Proparacaine HydrochlorideAltaire Pharmaceuticals Inc.
Salts
Name/CASStructureProperties
Proparacaine Hydrochloride
Thumb
  • InChI Key: BFUUJUGQJUTPAF-UHFFFAOYSA-N
  • Monoisotopic Mass: 330.171020447
  • Average Mass: 330.85
DBSALT000459
Categories
UNIIB4OB0JHI1X
CAS number499-67-2
WeightAverage: 294.3892
Monoisotopic: 294.194342708
Chemical FormulaC16H26N2O3
InChI KeyInChIKey=KCLANYCVBBTKTO-UHFFFAOYSA-N
InChI
InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
IUPAC Name
2-(diethylamino)ethyl 3-amino-4-propoxybenzoate
SMILES
CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentBenzoic acid esters
Alternative Parents
Substituents
  • Benzoate ester
  • Aminobenzoic acid or derivatives
  • Benzylether
  • Substituted aniline
  • Phenol ether
  • Benzoyl
  • Aniline
  • Alkyl aryl ether
  • Primary aromatic amine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed as a local (ophthalmic) anesthetic.
PharmacodynamicsProparacaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. More specifically, proparacaine appears to bind or antagonize the function of voltage gated sodium channels.
Mechanism of actionThe exact mechanism whereby proparacaine and other local anesthetics influence the permeability of the cell membrane is unknown; however, several studies indicate that local anesthetics may limit sodium ion permeability through the lipid layer of the nerve cell membrane. Proparacaine may alter epithelial sodium channels through interaction with channel protein residues. This limitation prevents the fundamental change necessary for the generation of the action potential.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Plasma

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Proparacaine Action PathwayDrug actionSMP00403
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9769
Blood Brain Barrier+0.8876
Caco-2 permeable+0.6501
P-glycoprotein substrateSubstrate0.7085
P-glycoprotein inhibitor INon-inhibitor0.7586
P-glycoprotein inhibitor IINon-inhibitor0.9645
Renal organic cation transporterNon-inhibitor0.7172
CYP450 2C9 substrateNon-substrate0.8202
CYP450 2D6 substrateNon-substrate0.5953
CYP450 3A4 substrateSubstrate0.5624
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9093
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5247
Ames testNon AMES toxic0.7542
CarcinogenicityNon-carcinogens0.7336
BiodegradationNot ready biodegradable0.9764
Rat acute toxicity2.5543 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8356
hERG inhibition (predictor II)Non-inhibitor0.5406
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
  • Pharmafair inc
  • Apothecon inc div bristol myers squibb
  • Allergan pharmaceutical
  • Optopics laboratories corp
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Taylor pharmacal co
Packagers
Dosage forms
FormRouteStrength
Solution/ dropsophthalmic
Solutionophthalmic5 mg/mL
Solution/ dropsophthalmic5 mg/mL
Prices
Unit descriptionCostUnit
Proparacaine hcl powder84.0USD g
Proparacaine HCl 0.5% Solution 15ml Bottle14.99USD bottle
Alcaine 0.5% eye drops2.19USD ml
Proparacaine 0.5% eye drops1.27USD ml
Ophthetic 0.5% eye drops1.02USD ml
Alcaine 0.5 % Solution0.68USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point182-183.3 °CNot Available
water solubilitySolubleNot Available
logP2.5Not Available
pKa3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.39 mg/mLALOGPS
logP2.97ALOGPS
logP2.6ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.79 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity86.04 m3·mol-1ChemAxon
Polarizability34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01HA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (118 KB)
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Proparacaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Proparacaine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Proparacaine.
AmisulprideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Azaperone.
AzelastineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Proparacaine.
BaclofenThe risk or severity of adverse effects can be increased when Proparacaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Proparacaine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
BrimonidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Proparacaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Proparacaine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Proparacaine.
ButacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Proparacaine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Proparacaine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Proparacaine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Proparacaine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Proparacaine.
CitalopramThe risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Proparacaine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Proparacaine.
CocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Proparacaine.
CyclizineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Proparacaine.
DapoxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Proparacaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Proparacaine.
DextromoramideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Proparacaine.
DezocineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
DoxylamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Proparacaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Proparacaine.
DrotebanolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.
EcgonineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Proparacaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Proparacaine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Proparacaine.
EntacaponeThe risk or severity of adverse effects can be increased when Proparacaine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Proparacaine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Proparacaine.
EthanolProparacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Proparacaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Proparacaine.
EthosuximideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Proparacaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Proparacaine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Proparacaine.
FluspirileneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Proparacaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Proparacaine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Proparacaine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Proparacaine.
HalothaneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Proparacaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Proparacaine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Proparacaine.
KetamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Proparacaine.
LithiumThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Proparacaine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Proparacaine.
Lu AA21004The risk or severity of adverse effects can be increased when Proparacaine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Proparacaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine.
MesoridazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Proparacaine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Proparacaine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methylphenobarbital.
MetyrosineProparacaine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine.
MilnacipranThe risk or severity of adverse effects can be increased when Proparacaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
MirtazapineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Proparacaine.
MolindoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Proparacaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.
NabiloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nalbuphine.
NitrazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Proparacaine is combined with Opium.
OrphenadrineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Proparacaine.
OsanetantThe risk or severity of adverse effects can be increased when Proparacaine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Proparacaine.
OxymorphoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paliperidone.
ParaldehydeProparacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Proparacaine.
ParoxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Proparacaine.
PerampanelThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Proparacaine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pomalidomide.
PramipexoleProparacaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Proparacaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Proparacaine.
PrimidoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Proparacaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Proparacaine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Proparacaine.
PromethazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Promethazine.
PropofolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Proparacaine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Proparacaine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Proparacaine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Proparacaine.
RomifidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Romifidine.
RopiniroleProparacaine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Proparacaine.
RotigotineProparacaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Proparacaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Proparacaine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Proparacaine.
SertindoleThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Proparacaine.
SuvorexantThe risk or severity of adverse effects can be increased when Proparacaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptProparacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Proparacaine.
TetrabenazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrodotoxin.
ThalidomideProparacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Proparacaine.
ThiamylalThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Proparacaine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Proparacaine.
ThiothixeneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Proparacaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Proparacaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proparacaine.
TrazodoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Proparacaine.
TrimipramineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Proparacaine.
VigabatrinThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Proparacaine.
ZolazepamThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Proparacaine.
ZonisamideThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23